Finally, we demonstrated that simultaneous high expression of ADAM9/VEGFA or ADAM9/ANGPT2 are linked to poor prognosis, which shows the clinical relevance of ADAM9-mediated vascular remodeling in lung cancer progression. This evidence concerns the gene VEGFA and lung carcinoma.